Advertisement
UK markets close in 6 hours 4 minutes

  • FTSE 100

    8,089.06
    +48.68 (+0.61%)
     

  • FTSE 250

    19,721.80
    +2.43 (+0.01%)
     

  • AIM

    755.27
    +0.58 (+0.08%)
     

  • GBP/EUR

    1.1672
    +0.0027 (+0.23%)
     

  • GBP/USD

    1.2516
    +0.0054 (+0.43%)
     

  • Bitcoin GBP

    51,166.73
    -1,961.66 (-3.69%)
     

  • CMC Crypto 200

    1,365.77
    -16.81 (-1.22%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    82.86
    +0.05 (+0.06%)
     

  • GOLD FUTURES

    2,338.60
    +0.20 (+0.01%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,980.83
    -107.87 (-0.60%)
     

  • CAC 40

    8,053.29
    -38.57 (-0.48%)
     
Property:

How to sell your home

Top tips from property investors

Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference

Achilles Therapeutics PLC
·1-min read

LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. ET.

A live and archived webcast of the presentation will be available in the Events & Presentations section of the Achilles website.

About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with unresectable locally advanced and metastatic non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Further information:

Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com